Estimating the OncotypeDX score: validation of an inexpensive estimation tool.

ABSTRACT:

Background

OncotypeDX, a multi-gene expression assay, has been incorporated into clinical practice as a prognostic and predictive tool. However, its use in resource-constrained international healthcare systems is limited. Here we develop and validate a simplified model using clinicopathologic criteria to predict OncotypeDX score.

Methods

Patients with estrogen receptor (ER) and/or progesterone receptor (PR)-positive and HER2-negative invasive ductal carcinoma for whom the OncotypeDX test was successfully performed between 09/2008 and 12/2011 were retrospectively identified. Tumor size, nuclear and histologic grade, lymphovascular invasion, and ER and PR status were extracted from pathology reports. Data were split into a training dataset comprising women tested 09/2008-04/20

SUBMITTER: Eaton AA 

PROVIDER: S-EPMC5310948 | biostudies-literature | 2017 Feb

REPOSITORIES: biostudies-literature